Background. Little is known of the long-term risks of bloodstream infection (BSI) with extended spectrum β-lactamase-producing Enterobacteriaceae (EPE) in previously-colonized individuals. We investigated EPE-BSI risks and associated risk factors during 6 years following EPE colonization.
the risk of EPE-BSI, but these studies have not focused on colonized individuals [10, [13] [14] [15] . Exposure to antibiotic drugs could exert selective pressure on the intestinal flora in colonized individuals, providing a competitive advantage and sustaining the ecological niche for EPE in the gut.
In Sweden, fecal screening cultures for EPE are commonly performed on patients seeking medical care after hospital admission abroad, residency in long-term care facilities, or contact tracing. Since 1 February 2007, all findings of EPE in clinical specimens at microbiological laboratories in Sweden have been reported to the national electronic system for communicable disease surveillance (SmiNet) at the Public Health Agency of Sweden. We used the nationwide register to perform a population-based cohort study to investigate the incidence of EPE-BSI up to 6 years after an individual's EPE-positive feces or urine culture, compared to the general population. Furthermore, we investigated the influence of socio-demographic factors, co-morbidities, and antibiotic usage on subsequent EPE-BSI risks in individuals with previous findings of EPE.
METHODS

Study Population
A nationwide population-based cohort was constructed of all Swedish citizens with a first-documented finding of EPE in feces (n = 5513) or urine (n = 17 189) in SmiNet between 1 February 2007 and 31 December 2012 ( Figure 1 and Supplementary Data). At the time, the Public Health Agency recommended fecal screening cultures in patients presenting to a hospital with a history of medical care within the last 6 months either in a foreign country or in a domestic hospital with an outbreak situation [16] . Urine cultures were recommend for suspected urinary tract infections, except for non-pregnant women with uncomplicated, non-recurrent cystitis without a recent stay in a high-prevalence country.
For each EPE-positive individual, 2 reference persons were matched by age (in years), sex, and county of residence from the general population using the total population register that contains data on all Swedish citizens ( Figure 1 and Supplementary  Table S1 ) [17] . For 243 of the exposed participants, there was only 1 matching comparison person available in the stratum. The comparison group totaled 45 161 subjects.
Exposures and Outcome
The subjects were linked to national health registers using unique Swedish personal identification numbers. Morbidity data was obtained from the hospital discharge register, which contains International Classification of Diseases (ICD-10) diagnoses and data on procedures for all hospital care administered in Sweden (Supplementary Table S2 ) [18] . Charlson comorbidity scores were calculated from ICD-10 codes [19, 20] . Data on the highest-attained education level (0-9, 10-12, >12 years) and immigration and emigration was obtained from the longitudinal integration database for health insurance and labor market studies. Pharmacy dispensations of systemic outpatient antibiotic drugs (Anatomical Therapeutic Chemical Classification System [ATC codes J01A-J01X]) were obtained from the Prescribed Drug Register. Antibiotic drugs were divided into groups by their mechanism of action.
Study subjects were followed until the occurrence of either the study outcome, emigration, death, or the end of the study period (31 December 2012). The outcome was defined as the first EPE-positive blood culture. Outcomes <30 days after the positive urine/feces culture were defined as prevalent and ≥30 days after the culture as incident.
SmiNet is a passive surveillance system. To improve capturing of EPE-BSIs, we performed active surveillance in all hospitals in Sweden by identifying subjects with gram-negative sepsis-related diagnoses (A415, A419, or N109) in the hospital discharge register during follow-up. All Swedish microbiological laboratories were contacted to confirm whether subjects had EPE-positive blood cultures. This procedure captured 70 additional outcomes, of which 40 were incident.
Statistical Analyses
The cumulative incidence function of EPE-BSIs was estimated using the Stata command stcompet [21] . The crude cumulative incidence was plotted by time. Cox regression was used to calculate cause-specific hazard ratios (CSHR) of EPE-BSIs in patients with baseline EPE findings, compared to the population reference group. The model was adjusted for matching variables, species of baseline bacterial culture, and Charlson comorbidity scores [22] . Survival analyses of risk factors within the urine and feces cohorts were limited to incident EPE-BSI episodes to avoid reverse causation. CSHRs of age, sex, species at baseline, sampling site (urine or feces), and comorbidity were estimated using Poisson regression to account the effect of time-on-study, using the categories 0-30, 31-91, 92-182, 183-365, 365-730, and ≥730 days [23, 24] . The association between antibiotic dispensation and incident EPE-BSI was analyzed using Cox regression, where antibiotic groups were analyzed separately, adjusted for age, sex, counties, baseline bacterial species and sources, Charlson comorbidity scores, and dispensation of other antibiotic classes. The antibiotic time-dependent effect was estimated by categorizing time into 8-30, 31-91, and 92-182 days after dispensation.
Likelihood ratio tests were performed to detect interactions between covariates and the source of the baseline EPE sample (urine or feces). Since there was no evidence of interaction (all P-values >.05, Supplementary Tables S4 and S5), the cohorts were analyzed together. Statistical analyses were performed using Stata version 12.0.
Ethics
The Stockholm Regional Ethics Council approved the study (No. 2012/2104-31/2).
RESULTS
Baseline Characteristics
The median age at baseline was 62 years (interquartile range: 36-77) in subjects with EPE in urine samples and 50 years (interquartile range: 28-68) in subjects with EPE in fecal samples. The percentage of females was 74.4% (12 791/17 189) in the urine cohort and 51.2% (2824/5513) in the feces cohort. Subjects in the urine and feces cohorts had higher prevalences of comorbidities than the reference groups from the general population (Charlson index scores ≥1: 47.9, 47.1, and 23.0%, respectively; Supplementary 
EPE-BSI in Subjects With Previous EPE Findings, Compared to General Population
A total of 660 EPE-BSI events occurred in the cohorts during up to 6 years of follow-up (mean follow-up time 2.1 years), of which 448 were prevalent and 212 were incident. All prevalent and 209 out of 212 (98.6%) incident events occurred in individuals with a previous finding of EPE in either feces or the urinary tract. Out of 660 EPE-BSIs, 522 (79.1%) were caused by E. coli, 57 (8.6%) by K. pneumoniae, 10 (1.5%) by Citrobacter species, 5 (0.8%) by Proteus species, and 66 (10.0%) by another species or the species was not reported. Out of 212 incident EPE-BSIs, 171 (80.7%) were caused by E. coli, 27 (12.7%) by K. pneumoniae, 2 (0.9%) by Citrobacter species, and 12 (5.7%) by another species or the species was not reported. From these 212, 29 (13.7%) incident events were caused by a different species than the bacteria isolated at baseline. Community-onset EPE-BSIs (culture performed within first 2 days of hospitalization) accounted for 167/212 (78.8%) events.
The cumulative incidence of EPE-BSIs during up to 6 years of follow-up was 3.8% (n = 591) among subjects with EPE detected in urine at baseline, 1.6% (n = 66) among subjects with EPE detected in feces, and 0.02% (n = 3) in the reference cohort from the general population ( Figure 2 and Table 1 ). The CSHRs for prevalent or incident EPE-BSIs, compared to the general population and adjusted for age, sex, residence county, baseline bacterial species, and Charlson comorbidity score, were 392.63 (95% confidence interval [CI] 120.17-1282.81) for the urine cohort and 117.74 (95% CI 35.10-394.88) for the feces cohort. Restricting the analysis to incident cases, the corresponding adjusted CSHR (aCSHR) was 61.47 (95% CI 15.29-247.15) and 31.94 (95% CI 7.58-134.56) for subjects in the urine and feces cohorts, respectively.
The incidence rates of EPE-BSI peaked at 181.0 and 1080.5 events per 1000 person-years during the first 7 days of follow-up in the feces and urine cohorts, respectively ( Table 1 ). The incidences decreased exponentially during the first 6 months in the feces cohort, to plateau at 2.2 events per 1000 person-years for the period of 6 months to 3.1 years after baseline. No outcomes occurred in the feces cohort for 3.1-6 years after baseline. In the urine cohort, the incidence decreased exponentially during the first year and averaged 2.3 per 1000 person-years during the remaining follow-up period. When compared to the general population, the incidences of EPE-BSIs were numerically elevated for 3 years in the feces cohort and for at least 5 years in the urine cohort. After <6, 6-12, and >12 months of follow-up in the urine and feces cohorts, the combined proportions of EPE-BSIs among subjects with incident ICD-10 gram-negative sepsis-related diagnoses were 16.5% (83/506), 8.4% (19/225), and 6.9% (40/581), respectively.
Risk Factors for Incident EPE-BSI in Subjects With Previous EPE Findings
The feces and urine cohorts were analyzed together, since no significant effect modification was present (Supplementary Table S4 and S5). A previous EPE-positive urine culture was associated with an aCSHR of 2.04 (95% CI 1.38-3.01) compared to a fecal culture (Table 2 ). K. pneumoniae was associated with an aCSHR of 1.82 (95% CI 1.24-2.67) compared to E. coli. Men had an aCSHR of 2.20 (95% CI 1.65-2.92) for EPE-BSI, whereas age was not a strong risk factor. The aCSHR increased from 2.40 (95% CI 1.34-4.30) for subjects with a Charlson score of 1 to 13.76 (95% CI 7.93-24.84) for Charlson scores ≥6. In a separate model, 9 disease groups were analyzed ( Table 2) . Out of these, urological disorders conferred the highest aCSHR, of 3.40 (95% CI 2.47-4.69), while immunological disorders, malignancies, diabetes, and chronic obstructive pulmonary disease had aCSHRs between 1.62 and 2.15. The highest-attained educational level was not significantly associated with EPE-BSIs in the adjusted model when restricted to the 16 572 subjects ≥25 years of age.
The association between outpatient antibiotics and EPE-BSIs was analyzed for up to 6 months after dispensation (Table 3) . Abbreviations: BSI, bloodstream infection; CI, confidence interval; EPE, extended-spectrum β-lactamase-producing Enterobacteriaceae. a Events per 1000 person-years. Limited to the first year after study entry.
b Adjusted for age, sex, county, species, site of sampling (urine or feces), Charlson comorbidity score, and consumption of other antibiotic classes.
c Phenoxymethylpenicillin (J01CE02) and isoxazolylpenicillin (J01CF01 and J01CF05).
d Penicillins with extended spectrums, including inhibitor combinations (Anatomical Therapeutic Chemical Classification System [ATC] starting with J01CA or J01CR).
e Any fluoroquinolone (ATC starting with J01MA).
f Includes trimethoprim-sulfametaxozole combinations (ATC starting with J01EA or J01EE).
g Antibiotics with selective activity against gram-negative bacilli, but mostly not EPE (trimethoprim-sulfamethoxazole, fluoroquinolones, oral cephalosporins, and penicillins with extended spectrums). Cephalosporins were not assessed as an individual group, as exposures were few.
dispensation. Overall, the majority of incident EPE-BSIs occurred in subjects with no exposure to the studied antibiotics (varying from 83.9% for fluoroquinolones to 94.0% for phenoxymethylpenicillins and isoxazolylpenicillins).
DISCUSSION
Based on this nationwide population-based cohort study, we determined 4 things that can influence future management of patients. First, individuals with a previously-documented finding of EPE in their urine or feces have 61-and 32-fold increased risks, respectively, of incident EPE-BSIs compared to the general population. Second, although the increased risk lasts for 3 years after a positive fecal culture and for at least 5 years after a positive urine culture, it diminishes considerably during the first year, to reach 2 per 1000 person-years at 6 months after a positive fecal culture and 1 year after a positive urine culture. Third, individuals with previous findings of EPE can be stratified into risk groups, where subjects with co-morbidities-in particular urological disorders-have increased risks of EPE-BSIs. For example, according to our model, a male with a current urological disorder and a previous urinary tract infection caused by ESBL-producing K. pneumoniae has a 14-fold increased relative risk of a subsequent EPE-BSI when compared to a woman without any urological disorder but who had a previous finding of ESBL-producing E. coli in her feces. Fourth, in subjects with a previous EPE finding, antibiotics with selective activity against gram-negative bacilli, but mostly not EPE, and pivmecillinam were associated with a doubled risk of developing a EPE-BSI for 3 months after dispensation. Yet, the attribution of outpatient antibiotic consumption to incident EPE-BSI was minor. This is, to our knowledge, the first large-scale cohort study to investigate the long-term risks of EPE-BSI in patients previously exposed to EPE in urine or feces. Our study gives important information about the natural history of EPE carriage and infection. It corroborates findings from case-control studies that previous EPE-positive cultures are important risk factors for subsequent EPE-BSIs [9] [10] [11] 25] . The incidence is particularly high during the first 6 months to 1 year after EPE findings in feces or urine, indicating that patients with a history of EPE in the previous year are at increased risk of EPE-BSIs if presenting with sepsis. This is in line with previous studies that show that carriage of EPE persists in 33-44% of study subjects for up to 1 year [26] [27] [28] . This gives important information in guidance of targeted therapies in antibiotic stewardship programs. The predictive capacities of specific time windows since the last EPE finding need to be validated in studies targeting patients with sepsis cases suspected to be caused by Enterobacteriaceae. In a Dutch study of patients with suspected gram-negative sepsis, the positive predictive value of a documented EPE colonization within the last 90 days for BSIs with bacteria resistant to third-generation cephalosporins was 7.4% [12] . Furthermore, we did not have access to complete data on cultures between the index culture at the start of follow-up and censoring. Hence, we could not model the effect of subsequent positive or negative fecal or urine cultures on the risks of EPE-BSIs.
Several case-control studies have identified antibiotic third-generation cephalosporins and fluoroquinolones as risk factors for EPE urinary tract infections and BSIs, and strategies to reduce ESBL dissemination often aim at decreasing their use [10, 25, [29] [30] [31] . However, there is limited evidence on how antibiotic usage influences risks in already-colonized patients. Small studies have yielded discrepant results as to whether antibiotic exposure impacts the length of intestinal EPE carriage [26, 28, 32, 33] . We observed an increased risk of an EPE-BSI for up to 3 months after dispensation of pivmecillinam and antibiotics with selective activity against gram-negative bacilli, but mostly not EPE. Our data gives some support to the hypothesis that exposure to certain antibiotics modifies the intestinal microbiota, thus making it more likely for EPE to cause invasive infections [34] . This needs confirmation in future studies, since we cannot rule out that the increased risk partly is explained by confounding or bias: for example, due to inadequately-treated urinary tract infections or unmeasured differences between treatment groups. Furthermore, we did not assess the effect of treatment length, and it is difficult to fully account for repeated antibiotic exposure or concomitant exposure to different antibiotics.
The strength of our study is that it was performed nationally with comprehensive follow-ups using Swedish health registers with high validity [17, 18] . This enabled us to compare risks in subjects with previous exposure in feces or urine with the general population. Since subjects from the general population differed from EPE-exposed patients, we performed adjustments for socio-economical host factors and co-morbidity. Nevertheless, due to the observational nature of the study, we cannot rule out residual or unmeasured confounding. Furthermore, we only had data on outpatient antibiotic dispensations at pharmacies, and could not verify actual intake of the drugs. Since ESBLs are located on plasmids, they can be horizontally transmitted to other bacteria. We did not have access to bacterial isolates and could not confirm that an individual's EPE-BSI was caused by the same strains as that isolated in their fecal or urine culture [28] . Indeed, 14% of incident EPE-BSIs were caused by a different species than the baseline sample. Furthermore, it would have been valuable to assess if clones, such as E. coli ST131 and, particularly, its sub-clone ST131-H30-Rx, are more prone to cause invasive infections, as has been suggested by previous studies [7] . This would indicate that sequence type could be used to differentiate risks among carriers. Several studies also reported that E. coli phylogroups B2 and ST131 are associated with prolonged carriage [26, 28, 35] . The European Society of Clinical Microbiology and Infectious Diseases does not recommend active screening cultures as a measure to control spread of multi-drug resistant gram-negative bacteria [36] . The feces cohort reflects Swedish screening practices, affecting the external validity of our findings. However, results from the urine cohort can readily be generalized to other settings and the risk factors we identified were similar in both cohorts.
In conclusion, as the prevalence of EPE carriage increases in hospitals and the community, it is important to quantify the risk of severe infections in specific patient groups. We have identified high-risk populations that can become targets for interventions such as eradication therapy and antibiotic stewardship programs [37] .
